Immunogenicity and protective efficacy of recombinant Modified Vaccinia virus Ankara candidate vaccines delivering West Nile virus envelope antigens (Q38789146)

From Wikidata

Jump to navigation Jump to search

scientific article published on 29 February 2016

Language	Label	Description	Also known as
English	Immunogenicity and protective efficacy of recombinant Modified Vaccinia virus Ankara candidate vaccines delivering West Nile virus envelope antigens	scientific article published on 29 February 2016

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Immunogenicity and protective efficacy of recombinant Modified Vaccinia virus Ankara candidate vaccines delivering West Nile virus envelope antigens (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

West Nile virus

0 references

object named as

Vaccinia virus

1 reference

based on heuristic

inferred from title

10

object named as

Albert D M E Osterhaus

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

object named as

Gerd Sutter

12

0 references

1

object named as

Asisa Volz

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Anna-Theresa Lülf-Averhoff

4

object named as

Anna Lülf

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Penelope Koraka

9

object named as

Penelope Koraka

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Gorben P. Pijlman

8

object named as

Gorben P Pijlman

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Byron E E Martina

11

object named as

Byron E Martina

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

2

object named as

Stephanie Lim

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

6

object named as

Sylvia Jany

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

author name string

Martina Kaserer

3

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Lisa Marr

5

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Cornelia A Deeg

7

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

language of work or name

0 references

publication date

29 February 2016

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

34

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

16

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

1915-1926

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

West Nile virus: an overview of its spread in Europe and the Mediterranean basin in contrast to its spread in the Americas

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.042

7 January 2021

Origin of the West Nile virus responsible for an outbreak of encephalitis in the northeastern United States

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.042

7 January 2021

West Nile virus and its emergence in the United States of America

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.042

7 January 2021

The outbreak of West Nile virus infection in the New York City area in 1999

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.042

7 January 2021

Flaviviruses and their antigenic structure

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.042

7 January 2021

Assembly and Maturation of the Flavivirus Kunjin Virus Appear To Occur in the Rough Endoplasmic Reticulum and along the Secretory Pathway, Respectively

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.042

7 January 2021

The zoonotic flaviviruses of southern, south-eastern and eastern Asia, and Australasia: the potential for emergent viruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.042

7 January 2021

Putative new West Nile virus lineage in Uranotaenia unguiculata mosquitoes, Austria, 2013.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.042

7 January 2021

The challenge of West Nile virus in Europe: knowledge gaps and research priorities

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.042

7 January 2021

Lineage 1 and 2 strains of encephalitic West Nile virus, central Europe

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.042

7 January 2021

Genetic characterization of West Nile virus lineage 2, Greece, 2010.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.042

7 January 2021

Recombinant canarypox vectored West Nile virus (WNV) vaccine protects dogs and cats against a mosquito WNV challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.042

7 January 2021

Protection provided by a recombinant ALVAC(®)-WNV vaccine expressing the prM/E genes of a lineage 1 strain of WNV against a virulent challenge with a lineage 2 strain.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.042

7 January 2021

Vaccines in development against West Nile virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.042

7 January 2021

A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.042

7 January 2021

A live, attenuated recombinant West Nile virus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.042

7 January 2021

Crystal Structure of the West Nile Virus Envelope Glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.042

7 January 2021

Quantifying the specific binding between West Nile virus envelope domain III protein and the cellular receptor alphaVbeta3 integrin

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.042

7 January 2021

Envelope protein glycosylation status influences mouse neuroinvasion phenotype of genetic lineage 1 West Nile virus strains

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.042

7 January 2021

Structural basis of West Nile virus neutralization by a therapeutic antibody

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.042

7 January 2021

Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.042

7 January 2021

Easy and efficient protocols for working with recombinant vaccinia virus MVA.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.042

7 January 2021

Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.042

7 January 2021

Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.042

7 January 2021

Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.042

7 January 2021

A mouse model of human adaptive immune functions: HLA-A2.1-/HLA-DR1-transgenic H-2 class I-/class II-knockout mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.042

7 January 2021

Functional processing and secretion of Chikungunya virus E1 and E2 glycoproteins in insect cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.042

7 January 2021

Epitope discovery in West Nile virus infection: Identification and immune recognition of viral epitopes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.042

7 January 2021

Development of a strand-specific real-time qRT-PCR for the accurate detection and quantitation of West Nile virus RNA.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.042

7 January 2021

Technologies for the development of West Nile virus vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.042

7 January 2021

Preclinical studies of a modified vaccinia virus Ankara-based HIV candidate vaccine: antigen presentation and antiviral effect

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.042

7 January 2021

Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.042

7 January 2021

Preclinical evaluation of a modified vaccinia virus Ankara (MVA)-based vaccine against influenza A/H5N1 viruses.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.042

7 January 2021

Recombinant modified vaccinia virus Ankara expressing the hemagglutinin gene confers protection against homologous and heterologous H5N1 influenza virus infections in macaques.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.042

7 January 2021

Recombinant modified vaccinia virus Ankara-based vaccine induces protective immunity in mice against infection with influenza virus H5N1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.042

7 January 2021

Induction of influenza (H5N8) antibodies by modified vaccinia virus Ankara H5N1 vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.042

7 January 2021

Identification of an epitope on the dengue virus membrane (M) protein defined by cross-protective monoclonal antibodies: design of an improved epitope sequence based on common determinants present in both envelope (E and M) proteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.042

7 January 2021

The structural immunology of antibody protection against West Nile virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.042

7 January 2021

Monoclonal antibody against Saint Louis encephalitis prM viral protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.042

7 January 2021

Protective efficacy in mice of a secreted form of recombinant dengue-2 virus envelope protein produced in baculovirus infected insect cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.042

7 January 2021

Recombinant vaccinia virus expressing PrM and E glycoproteins of louping ill virus: induction of partial homologous and heterologous protection in mice.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.042

7 January 2021

A recombinant novirhabdovirus presenting at the surface the E Glycoprotein from West Nile Virus (WNV) is immunogenic and provides partial protection against lethal WNV challenge in BALB/c mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.042

7 January 2021

Virus-like particles in vaccine development.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.042

7 January 2021

West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.042

7 January 2021

Live measles vaccine expressing the secreted form of the West Nile virus envelope glycoprotein protects against West Nile virus encephalitis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.042

7 January 2021

N-Linked Glycosylation of West Nile Virus Envelope Proteins Influences Particle Assembly and Infectivity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.042

7 January 2021

Effects of the number of amino acid residues in the signal segment upstream or downstream of the NS2B-3 cleavage site on production and secretion of prM/M-E virus-like particles of West Nile virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.042

7 January 2021

Structure of Immature West Nile Virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.042

7 January 2021

Molecular biology of flaviviruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.042

7 January 2021

Efficient Assembly and Secretion of Recombinant Subviral Particles of the Four Dengue Serotypes Using Native prM and E Proteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.042

7 January 2021

The memory T cell response to West Nile virus in symptomatic humans following natural infection is not influenced by age and is dominated by a restricted set of CD8+ T cell epitopes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.042

7 January 2021

Recent progress in West Nile virus diagnosis and vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.042

7 January 2021

West Nile virus-specific CD4 T cells exhibit direct antiviral cytokine secretion and cytotoxicity and are sufficient for antiviral protection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.042

7 January 2021

CD8 and CD4 T cells in west nile virus immunity and pathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.042

7 January 2021

Protective capacity and epitope specificity of CD8(+) T cells responding to lethal West Nile virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.042

7 January 2021

Role of CD8+ T cells in control of West Nile virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.042

7 January 2021

Key role of T cell defects in age-related vulnerability to West Nile virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.02.042

7 January 2021

Identifiers

10.1016/J.VACCINE.2016.02.042

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

release_iimbl5qmdbcp5oarhbwfi6rvnu

1 reference

https://api.fatcat.wiki/v0/release/iimbl5qmdbcp5oarhbwfi6rvnu

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38789146&oldid=1898987015"